Yang-Hui Huang

605 total citations
29 papers, 479 citations indexed

About

Yang-Hui Huang is a scholar working on Oncology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Yang-Hui Huang has authored 29 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 19 papers in Molecular Biology and 13 papers in Infectious Diseases. Recurrent topics in Yang-Hui Huang's work include Drug Transport and Resistance Mechanisms (28 papers), Cancer therapeutics and mechanisms (15 papers) and HIV/AIDS drug development and treatment (13 papers). Yang-Hui Huang is often cited by papers focused on Drug Transport and Resistance Mechanisms (28 papers), Cancer therapeutics and mechanisms (15 papers) and HIV/AIDS drug development and treatment (13 papers). Yang-Hui Huang collaborates with scholars based in Taiwan and United States. Yang-Hui Huang's co-authors include Chung‐Pu Wu, Sung-Han Hsiao, Suresh V. Ambudkar, Tai‐Ho Hung, Sabrina Lusvarghi, Yu‐Shan Wu, Yanqing Li, Sheng‐Chieh Hsu, Megumi Murakami and Hong‐May Sim and has published in prestigious journals such as Cancer Research, International Journal of Molecular Sciences and Biochemical Pharmacology.

In The Last Decade

Yang-Hui Huang

29 papers receiving 474 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yang-Hui Huang Taiwan	12	308	302	93	52	45	29	479
Sung-Han Hsiao Taiwan	14	308 1.0×	299 1.0×	99 1.1×	45 0.9×	42 0.9×	22	471
Guan-Nan Zhang United States	12	277 0.9×	249 0.8×	63 0.7×	23 0.4×	31 0.7×	17	425
Csilla Hegedüs Hungary	11	351 1.1×	217 0.7×	60 0.6×	22 0.4×	50 1.1×	13	444
Yue-Li Sun China	10	230 0.7×	248 0.8×	33 0.4×	31 0.6×	59 1.3×	23	535
Clara Lemos Netherlands	9	297 1.0×	451 1.5×	29 0.3×	66 1.3×	52 1.2×	10	698
Agnès Basseville United States	11	239 0.8×	321 1.1×	31 0.3×	23 0.4×	32 0.7×	18	521
Maria A.J. van Eijndhoven Netherlands	7	356 1.2×	258 0.9×	52 0.6×	19 0.4×	73 1.6×	8	520
Bing Zhao China	10	168 0.5×	164 0.5×	49 0.5×	40 0.8×	64 1.4×	29	360
Mário Šereš Slovakia	13	261 0.8×	337 1.1×	31 0.3×	38 0.7×	18 0.4×	26	536
Yan‐jun Mi China	10	424 1.4×	331 1.1×	59 0.6×	33 0.6×	185 4.1×	15	700

Countries citing papers authored by Yang-Hui Huang

Since Specialization

Citations

This map shows the geographic impact of Yang-Hui Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yang-Hui Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yang-Hui Huang more than expected).

Fields of papers citing papers by Yang-Hui Huang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yang-Hui Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yang-Hui Huang. The network helps show where Yang-Hui Huang may publish in the future.

Co-authorship network of co-authors of Yang-Hui Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Yang-Hui Huang. A scholar is included among the top collaborators of Yang-Hui Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yang-Hui Huang. Yang-Hui Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Chung‐Pu, Megumi Murakami, Yu‐Shan Wu, et al.. (2024). ABCG2 Mediates Resistance to the Dual EGFR and PI3K Inhibitor MTX-211 in Cancer Cells. International Journal of Molecular Sciences. 25(10). 5160–5160. 1 indexed citations

Murakami, Megumi, Yu‐Shan Wu, Yang-Hui Huang, et al.. (2024). Epertinib counteracts multidrug resistance in cancer cells by antagonizing the drug efflux function of ABCB1 and ABCG2. Biomedicine & Pharmacotherapy. 180. 117542–117542. 1 indexed citations

Murakami, Megumi, Yang-Hui Huang, Tai‐Ho Hung, et al.. (2024). The colony-stimulating factor-1 receptor inhibitor edicotinib counteracts multidrug resistance in cancer cells by inhibiting ABCG2-mediated drug efflux. Biomedicine & Pharmacotherapy. 180. 117554–117554. 1 indexed citations

Wu, Chung‐Pu, Ya‐Ju Hsieh, Megumi Murakami, et al.. (2023). ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines. Cells. 12(7). 1056–1056. 7 indexed citations

Wu, Chung‐Pu, Megumi Murakami, Sung-Han Hsiao, et al.. (2023). Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells. International Journal of Molecular Sciences. 24(18). 13972–13972. 7 indexed citations

Wu, Chung‐Pu, Megumi Murakami, Yu‐Shan Wu, et al.. (2022). P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhibitor Ensartinib in Cancer Cells. Cancers. 14(9). 2341–2341. 11 indexed citations

Li, Yanqing, Megumi Murakami, Yang-Hui Huang, et al.. (2022). Hydroxygenkwanin Improves the Efficacy of Cytotoxic Drugs in ABCG2-Overexpressing Multidrug-Resistant Cancer Cells. International Journal of Molecular Sciences. 23(21). 12763–12763. 2 indexed citations

Wu, Chung‐Pu, Ya‐Ju Hsieh, Yang-Hui Huang, et al.. (2022). The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2. Biomedicine & Pharmacotherapy. 154. 113663–113663. 6 indexed citations

Wu, Chung‐Pu, Megumi Murakami, Yu‐Shan Wu, et al.. (2022). The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biomedicine & Pharmacotherapy. 149. 112922–112922. 9 indexed citations

10.

Wu, Chung‐Pu, Sabrina Lusvarghi, Sung-Han Hsiao, et al.. (2021). Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat. International Journal of Molecular Sciences. 22(5). 2592–2592. 10 indexed citations

11.

Wu, Chung‐Pu, Tai‐Ho Hung, Sabrina Lusvarghi, et al.. (2021). The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biochemical Pharmacology. 188. 114516–114516. 29 indexed citations

12.

Wu, Chung‐Pu, Megumi Murakami, Yu‐Shan Wu, et al.. (2021). Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. Frontiers in Cell and Developmental Biology. 9. 699571–699571. 9 indexed citations

13.

Wu, Chung‐Pu, Yanqing Li, Tai‐Ho Hung, et al.. (2021). Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs. Journal of Natural Products. 84(9). 2544–2553. 8 indexed citations

14.

Wu, Chung‐Pu, Sabrina Lusvarghi, Yang-Hui Huang, et al.. (2020). Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. Biochemical Pharmacology. 180. 114137–114137. 21 indexed citations

15.

Wu, Chung‐Pu, Tai‐Ho Hung, Sung-Han Hsiao, et al.. (2020). Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. Cancers. 12(6). 1366–1366. 33 indexed citations

16.

Wu, Chung‐Pu, Sabrina Lusvarghi, Sung-Han Hsiao, et al.. (2020). Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Journal of Natural Products. 83(5). 1461–1472. 28 indexed citations

17.

Hsiao, Sung-Han, Sabrina Lusvarghi, Yang-Hui Huang, et al.. (2019). The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Cancer Letters. 445. 34–44. 32 indexed citations

18.

Wu, Chung‐Pu, Megumi Murakami, Sung-Han Hsiao, et al.. (2017). Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells. Molecular Pharmaceutics. 14(7). 2368–2377. 20 indexed citations

19.

Wu, Chung‐Pu, Sung-Han Hsiao, Hong‐May Sim, et al.. (2013). Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1. Biochemical Pharmacology. 86(7). 904–913. 29 indexed citations

20.

Wu, Chung‐Pu, Hong‐May Sim, Yang-Hui Huang, et al.. (2012). Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochemical Pharmacology. 85(3). 325–334. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact